(MRNY) YieldMax MRNA Option Income - Overview

ETF Category: Derivative Income | Exchange NYSE ARCA (USA) | Currency USD | Market Cap: 125m | Total Return 43.3% in 12m

Etf: Options, Derivatives, Single-Stock, Covered-Call, Non-Diversified

Total Rating 75
Risk 61
Buy Signal -0.03
Derivative Income -0.2
TER: 0.99%
AUM: 125m
Avg Trading Vol: 3.62M USD
ATR: 5.08%
Peers RS (IBD): 99.2
Risk 5d forecast
Volatility 49.0%
Relative Tail Risk -7.93%
Reward TTM
Sharpe Ratio 0.87
Alpha 19.80
Character TTM
Beta 1.187
Beta Downside 1.813
Drawdowns 3y
Max DD 82.04%
CAGR/Max DD -0.30

Risks

Technicals: choppy

Description: MRNY YieldMax MRNA Option Income February 27, 2026

The YieldMax MRNA Option Income Strategy ETF (MRNY) follows a focused investment approach that aligns its holdings with Moderna Inc. (MRNA), maintaining exposure even during adverse market or economic conditions while allowing for temporary defensive positioning. The fund is classified as a non-diversified, derivative-income ETF.

Recent data underscore the relevance of this strategy: Moderna reported Q4 2023 revenue of $5.2 billion, a 12 % YoY increase driven by its mRNA vaccine pipeline, while the global mRNA therapeutics market is projected to grow at a CAGR of 15 % through 2030. Additionally, implied volatility for biotech options, a key driver of MRNY’s income generation, remains elevated at around 38 % (VIX-Biotech), supporting higher option premiums.

For a deeper dive, you might explore ValueRay’s analysis of MRNY.

Headlines to watch out for

  • MRNA stock performance dictates MRNY option income
  • Volatility in MRNA shares impacts premium generation
  • Interest rate changes affect option valuation models
  • Regulatory actions on Moderna drug pipeline pose risk

What is the price of MRNY shares?

As of March 27, 2026, the stock is trading at USD 19.09 with a total of 82,412 shares traded.
Over the past week, the price has changed by +2.07%, over one month by +3.76%, over three months by +53.19% and over the past year by +43.27%.

Is MRNY a buy, sell or hold?

YieldMax MRNA Option Income has no consensus analysts rating.

What are the forecasts/targets for the MRNY price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -